{"id":"W4389279899","doi":"10.1016/j.annonc.2023.10.282","title":"147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Cancer Institute; Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; Novartis Pharma; University of California, San Francisco; AstraZeneca; Genentech; F. Hoffmann-La Roche; Clinical Trial Center, China Medical University Hospital; Humanitas Research Hospital; Sirtex Medical; Teijin Pharma; Humanitas University; Eli Lilly and Company; EA Pharma Co., Ltd.; Ludwig-Maximilians-Universität München; Universidad de Navarra; Kyowa Hakko Kirin; Khon Kaen University; Bayer HealthCare; MacroGenics; Relay Therapeutics; Daiichi Sankyo Europe; Agios Pharmaceuticals; Kanazawa University; Regeneron Pharmaceuticals; Boston Scientific Corporation; Mylan; EMD Serono; Flatiron Health; Kindai University; Ipsen; Jazz Pharmaceuticals; Exelixis; Celgene; Yakult Honsha; Astellas Pharma; University of Ulsan; Chinese University of Hong Kong; BeiGene; Memorial Sloan-Kettering Cancer Center; Pfizer; Servier; Incyte; Gilead Sciences; Taiho Pharmaceutical; Eisai; FibroGen; Universitat de Barcelona; Amgen; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Jounce Therapeutics; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Durvalumab; Tremelimumab; Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003520015,0.0004320693,0.001649478,0.000574298,0.0003325431,0.001442083,0.0006807275,0.0004841492,0.002331634],"category_scores_gemma":[0.002479676,0.0002456028,0.0011439,0.001497093,0.0001851055,0.0005640647,0.0006146855,0.001398427,0.0006630357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001256077,"about_ca_system_score_gemma":0.001696268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004634465,"about_ca_topic_score_gemma":0.01313395,"domain_scores_codex":[0.9993799,0.0002509799,0.00004615383,0.00003861976,0.0002060301,0.00007836228],"domain_scores_gemma":[0.9981648,0.0005962727,0.0003462331,0.0001527615,0.0004667356,0.0002732225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.08088735,0.001236844,0.0790614,0.003180993,0.009069571,0.0004319435,0.0003131903,0.003272563,0.006453977,0.0007359268,0.1237996,0.6915567],"study_design_scores_gemma":[0.04901404,0.02022815,0.6004736,0.001518725,0.02042796,0.001378224,0.0002363668,0.001833791,0.004330226,0.001365748,0.2990542,0.000139007],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6359823,0.1658257,0.004491415,0.02066572,0.003167627,0.002874733,0.1220637,0.0005144914,0.04441424],"genre_scores_gemma":[0.7559003,0.0730852,0.007030058,0.01386443,0.00254532,0.003073898,0.1328649,0.0003132978,0.01132265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004634465,"threshold_uncertainty_score":0.01861584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2221015040730366,"score_gpt":0.3656108423830158,"score_spread":0.1435093383099791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}